Dr Reddy’s CEO On Payer Dynamics, China Commitment And Disruption

Dr. Reddy's Laboratories Ltd. (DRL) continues to chisel and recalibrate its operations in the backdrop of a tough business environment in key markets like the US, but the Indian firm also expects to put the pedal to the metal in China, a market where it has had a long-standing base.(Also see "Big Cost Cuts At Dr Reddy’s, US Big Ticket Launch Progress Is Key" - Scrip, 27 July, 2018.)(Also see "India Pharma Firms Eye China, Dr Reddy’s Sees ‘Great Opportunity’ There" - Scrip, 29 October, 2018.)

In an interview with Scrip at the sidelines of the recently concluded India Pharmaceutical Forum in Mumbai, DRL’s co-chair and CEO GV Prasad maintained that only firms that operate in a "lean and mean fashion" will make money in the US - though not quite like in previous